

**Author(s):** Aken Desai, Michael Mathis, 2008

**License:** Unless otherwise noted, this material is made available under the terms of the **Creative Commons Attribution – Share Alike 3.0**

**License:** <http://creativecommons.org/licenses/by-sa/3.0/>

**We have reviewed this material** in accordance with U.S. Copyright Law **and have tried to maximize your ability to use, share, and adapt it.**

Copyright holders of content included in this material should contact [open.michigan@umich.edu](mailto:open.michigan@umich.edu) with any questions, corrections, or clarification regarding the use of content.

For more information about **how to cite** these materials visit <http://open.umich.edu/education/about/terms-of-use>.

**Student works** are presented **as is** and may be an interpretation of faculty members' lectures or assignments. These student works are **not a product of faculty members**. Faculty do not guarantee the accuracy of student work nor endorse them in any way.

Any **medical information** in this material is intended to inform and educate and is **not a tool for self-diagnosis** or a replacement for medical evaluation, advice, diagnosis or treatment by a healthcare professional. Please speak to your physician if you have questions about your medical condition.

**Viewer discretion is advised:** Some medical content is graphic and may not be suitable for all viewers.

# Transplantation Self Study

Tuesday, February 19, 2008  
4:00 PM

- Basics
  - Transplantation performed to replace non-functioning vital organ
  - Risk include (not limited to) rejection and immunosuppressants-->infection
- ABO Matching
  - Mismatching leads to endothelial damage by ABO antibodies
  - Subsequent widespread thrombosis and graft loss
  - O cannot accept A, B, AB
  - A cannot accept B, AB; B cannot accept A, AB
  - AB can accept everything
  - Hyperacute rejection
    - w/in hours
    - Antibody mediated
    - Marked by expanded inflammatory infiltrate composed of mononuclear lymphocytes
  - Acute and chronic rejection mediated by T cells
- MHC Rejection
  - T cell mediated
  - HLA molecules in MHC most important
  - Syngeneic grafts (same donor/recipient) never rejected
  - If HLA antigens not identical, T cells will react against foreign HLA molecules
  - Matching
    - HLA-identical siblings optimal
    - Post-transplant immunosuppression required for all transplant pairs except identical twins
  - MHC antigens
    - Self proteins loaded into HLA peptide groove
    - Even when HLA antigens identical, differences in self-peptides from donor organ can facilitate immune response
  - Matching
    - MHC matching sufficient but minor histocompatibility antigens not matched
    - T cells clones recognizing allogenic MHC molecules are abundant
    - Better matching results in lower likelihood of rejection and better response to immunosuppressants
    - T cells for minor antigens less abundant and well controlled immunosuppressants
- Immunosuppression
  - Increases risk of infection
  - NSAIDs
    - Reduce inflammation by inhibiting enzymes
    - Aspirin, ibuprofen, acetaminophen, naproxen
  - Corticosteroids
    - Prednisone
    - Inhibit antigen driven T cell differentiation by inhibiting expression of genes
    - Lead to apoptosis of activated T cells
    - Suppress action of inflammatory cells reducing both PG and LT synthesis and inhibiting emigration of leukocytes from blood vessels
    - SE: fluid retention, weight gain, diabetes, bone mineral loss, thinning of skin
  - Anti-metabolic drugs
    - Azathioprine, cyclophosphamide, mycophenolate
    - Act by killing all dividing cells
    - Nucleoside analogs that inhibit nucleotide synthesis or by alkylating DNA

- Act by killing T cells and B cells undergoing antigen driven differentiation
    - SE: bone marrow stem cells, skin, hair follicles, epithelial cells in intestine, fetus
  - Immunosuppressive drugs
    - Prevent signaling that is important to antigen-dependent T and B cell differentiation
    - Bind to cytoplasmic proteins that prevent signal transduction from T cell or Ig receptor via calcineurin (cyclosporin A and tacrolimus) or inhibit protein translation and progress through cell cycle (rapamycin)
    - Cyclosporin A/tacrolimus lead to reduced expression of cytokines
    - Rapamycin leads to T cell apoptosis
    - Agents are very effective inhibitors of antigen-driven immune responses
  - Combo of drugs usually used
    - Using smaller doses but multiple groups inhibition is improved but w/ less side effects
    - General immunosuppression still exists
- Matching
  - Type for MHC expressed on leukocytes using antibodies
    - Antibodies for a single allele difficult to obtain
    - Many alleles cannot be typed w/ antibodies, esp. class II genes
  - Type for MHC genes by PCR and sequencing
    - Finds all potential differences
    - Expensive and time consuming
    - Method of choice if time not major issue
  - Mixed Lymphocyte Rxn
    - MLR is co-culture from two individuals
    - Detects ability of T cells to recognize allogenic differences of WBC from another individual
    - T cells divide after recognition
    - Cell division can be measured by uptake of tritiated thymidine from culture media into cells
    - Negative control is potential graft recipients rxn to his/her own lymphocytes
    - Test is recipients lymphocytes reacting to donor's x-irradiated lymphocytes
    - Differences in class II are key differences that result in thymidine uptake
    - Sensitive measure of immunological recognition
    - Availability of suitable reagents is not an issue
    - Takes about a week and is expensive
- Bone Marrow Transplantation: Graft-versus-host disease also occurs
  - Hematopoietic stem cell transplantation: effective after transplantation b/c stem cells go to bone marrow and reconstitute all components of bone marrow
  - GVHD caused by mature T cells that contaminate bone marrow or stem cell preparation
    - Donor T cells recognize allogenic MHC molecules of host or minor HC antigens
    - Initiate inflammatory immune response against host tissue
    - Syngeneic > Genotypic-identical sibling > Other family member > Matched unrelated donor
      - The probability that any two unrelated persons will match is extremely low
      - Broad application of this technique is made feasible by large volunteer registries
  - Conditioning regimens
    - Bone marrow transplant recipients undergo chemo/radiation to reduce GVHD chance
      - Tumor burden w/ cytotoxic drugs
      - Immunosuppress recipient to prevent rejection of bone marrow transplant
  - Complications of transplant
    - Toxicity from conditioning regiment: short and long term effects
    - Graft rejection
    - GVHD
      - Acute
        - ◆ Usu. Develops w/in first 100 d of transplant
        - ◆ Primary tgts are skin, liver, intestines
      - Chronic

- ◆ Clinically represents autoimmune disease
- ◆ Skin (scleroderma), dry eyes, mouth and vagina (sicca like syndrome), liver, GI, lungs, fasciitis, serositis